Compare AMBA & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBA | HCM |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1811 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2011 | N/A |
| Metric | AMBA | HCM |
|---|---|---|
| Price | $50.42 | $13.93 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 9 | 1 |
| Target Price | ★ $97.25 | $13.75 |
| AVG Volume (30 Days) | ★ 911.2K | 20.7K |
| Earning Date | 02-26-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $295,402,000.00 | N/A |
| Revenue This Year | $15.69 | $28.37 |
| Revenue Next Year | $13.06 | $17.50 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $38.90 | $11.51 |
| 52 Week High | $96.69 | $19.50 |
| Indicator | AMBA | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 31.98 | 44.22 |
| Support Level | N/A | $13.92 |
| Resistance Level | $71.00 | $14.80 |
| Average True Range (ATR) | 2.15 | 0.35 |
| MACD | 0.17 | 0.03 |
| Stochastic Oscillator | 7.16 | 20.77 |
Ambarella Inc is a developer of semiconductor processing solutions for high-definition video capture, sharing, and display. The firm's solutions are sold to original design manufacturers and original equipment manufacturers to be designed for use in infrastructure broadcast encoders, wearable device cameras, automotive cameras, security cameras, consumer cameras, and industrial and robotic applications. The company's system-on-a-chip designs, based on its proprietary technology platform, are configurable to applications in various end markets. Geographical presence in Taiwan, Asia Pacific, Europe, North America, and the United States. The firm derives the majority of its revenue from Taiwan.
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.